Ernexa Therapeutics (NASDAQ:ERNA) Announces Quarterly Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) posted its quarterly earnings data on Monday. The company reported ($6.95) earnings per share for the quarter, Zacks reports.

Ernexa Therapeutics Stock Performance

NASDAQ:ERNA traded up $6.42 during mid-day trading on Tuesday, reaching $13.63. The stock had a trading volume of 14,472,455 shares, compared to its average volume of 1,048,022. The business has a 50 day simple moving average of $5.89 and a 200 day simple moving average of $20.80. Ernexa Therapeutics has a twelve month low of $3.18 and a twelve month high of $100.46. The firm has a market capitalization of $15.94 million, a price-to-earnings ratio of -0.19 and a beta of 1.88.

Ernexa Therapeutics News Summary

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and maintained a $30 price target, signaling confidence in the company’s longer-term outlook despite recent losses. Brookline Capital Markets earnings estimates for ERNA
• Neutral Sentiment: Ernexa Therapeutics released a virtual investor KOL Connect segment focused on the ovarian cancer landscape and its lead candidate, ERNA-101, which may help keep investor attention on the pipeline. ERNA-101 investor update article
• Negative Sentiment: The company reported a much wider-than-expected quarterly loss of ($6.95) per share, well below the consensus estimate of ($1.95), highlighting ongoing profitability pressure. ERNA earnings miss
• Negative Sentiment: Trading in ERNA was halted multiple times this morning due to LULD pauses, reflecting extreme volatility and rapid price swings that often accompany thinly traded biotech names. ERNA trading halts

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on ERNA shares. Weiss Ratings restated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research note on Tuesday, April 21st. Brookline Capital Markets started coverage on shares of Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Ernexa Therapeutics to a “hold” rating in a research note on Saturday. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.00.

Institutional Investors Weigh In On Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new stake in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to its most recent filing with the SEC. The firm purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent quarter. 70.55% of the stock is currently owned by hedge funds and other institutional investors.

Ernexa Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.